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Ovarian cancer is less prevalent in Japan than in Western coun-
tries, although the number of patients with ovarian cancer has been
increasing in Japan (Barber, 1993). In both areas, surface epithe-
lial-stromal tumours are the commonest, comprising about 60% of
all ovarian neoplasms or over 80% of primary ovarian malignan-
cies (Katsube et al, 1982; Koonings et al, 1989). Epithelial ovarian
cancers have the poorest prognosis among gynaecological malig-
nancies (Brinton and Hoover, 1992). To establish appropriate
therapeutic modalities in these tumours, information for factors
affecting prognosis is essential. Factors reported to influence the
prognosis include performance status, age of patients, cell type
(mucinous and clear cell), stage of disease, clinically measurable
disease, tumour volume, presence or absence of ascites, tumour
ploidy, expression of platelet-derived growth factor, HER-2/neu,
or Ki-67 counts (Rodenburg et al, 1987; Slamon et al, 1989;
Omura et al, 1991; Henriksen et al, 1993; Garzetti et al, 1995).
Bcl-2 is an oncoprotein known to inhibit programmed cell death
(McDonnell et al, 1989; Hockenbery et al, 1990), and expression
of this protein was correlated with favourable prognosis in lung,
breast and ovarian cancers (Pezella et al, 1993; Joensuu et al,
1994; Henriksen et al, 1995). Bax, one of the bcl-2 superfamily
proteins, induces apoptosis via heterodimerization with bcl-2, and
absence or diminished expression of Bax gene in neuroblastoma
(Hoehner et al, 1997) and neuroendocrine tumours of lung resulted
in longer survival (Brambilla et al, 1996).
Fas (CD95), a member of the tumour necrosis factor (TNF)
receptor family, is weakly expressed in many tissues, but strongly
expressed in the human liver, heart, lung, kidney, ovary and
activated lymphocytes (Nagata and Golstein, 1995). On the other
hand, Fas ligand (Fas L/CD95 L) expression is observed in
activated T- and NK-cells (Tanaka et al, 1996). Various cancer cell
lines also express Fas L and induce Fas-mediated apoptosis in
vitro in B-cell and T-cell lymphoma cell lines. Because Fas L
expressions in vivo are reported in human carcinomas including
melanoma, hepatocellular carcinoma, lung carcinoma, colon carci-
noma, non-Hodgkin’s lymphomas, oesophageal carcinoma and
pancreatic adenocarcinoma (Hahne et al, 1996; Strand et al, 1996;
Niehans et al, 1997; Shiraki et al, 1997; Bennett et al, 1998;
Müllauer et al, 1998; Ungefroren et al, 1998), a similar mechanism
might work in vivo, resulting in evasion of human tumours from
immune surveillance.
In the current study, protein expression of Fas and Fas L
together with bcl-2 and bax genes are examined in epithelial
ovarian neoplasms including adenoma, tumour with low potential
malignancy and carcinoma. Prognostic significance of the findings
was evaluated.
PATIENTS AND METHODS
A total of 132 epithelial ovarian neoplasms, including 36
adenomas (25 serous, ten mucinous and one Müllerian), 33
tumours of low potential malignancy (LPM) (14 serous, 17 muci-
nous and two Müllerian) and 63 carcinomas (33 serous, five muci-
nous, 13 endometrioid and 12 clear cell), were retrieved from the
surgical pathology files of Osaka University Hospital (OUH) and
Osaka Police Hospital (OPH). These patients were admitted to the
hospitals during the period from June 1991 to November 1997
(OUH), and March 1980 to December 1997 (OPH). Brief clinical
data were available in all patients together with follow-up data in
38 with carcinoma (OPH). In 35 carcinoma patients with adequate
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tomy with salpingo-oophorectomy (SO) in 26 cases, semiradical
hysterectomy in two, supracervical hysterectomy with SO in two,
probe laparotomy in two, and SO, radical hysterectomy and
volume reduction surgery in one each (Table 1). Of these 35
patients, all but one received chemotherapy; PAC (cisplatin,
doxorubicin and cyclophosphamide) in 30, CP, FAM (5-fluoro-
uracil, doxorubicin and mitomycin C), etoposide and mitomycin C
in one each. Five patients received chemotherapy prior to opera-
tion. There are no significant differences in modalities of surgery
and chemotherapy between Fas L-positive and negative groups.
Clinical parameters including age and clinical stage are shown
in Table 2, showing no significant differences between Fas
L-positive and -negative groups.
Histologic specimens were fixed in 10% formalin and routinely
processed for paraffin embedding. Histologic sections, cut at
3 mm, were stained with haematoxylin and eosin and immuno-
peroxidase procedures. Histological subclassification and grading
were performed by two pathologists (SM, MT).
Immunohistochemistry
Sections were deparaffinized in three changes of d-limonene
(Hemo De) (Fisher Chemical, PA, USA). After microwave oven
heating (100°C, 15 min) with H2800 Microwave Processor
(Energy Beam Sciences Inc., MA, USA) in citrate buffer (pH 6.0),
sections were processed with use of LSAB kit (Dako, Kyoto,
Japan). Primary monoclonal antibodies used were anti-bcl-2
Fas L expression in epithelial ovarian neoplasms 1447
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Table 1 Modalities of surgery and chemotherapy in patients with ovarian carcinoma (n = 35)
Number of Methods of surgery
Chemotherapy
Fas L expression Stage patients (Number of patients) Pre-operative Post-operative
Fas L-positive (n = 22) 1 7 STH + SO (6) 0 PAC (7)
SRH + LN (1)
2 2 STH + SO (2) 0 PAC (1)
FAM (1)
3 10 STH + SO (5) 2 PAC (9)
SRH (1) Etoposide (1)
RH (1)
Total reduction (1)
SO (1)
PL (1)
4 3 STH + SO (1) 2 PAC (3)
SCH + SO (2)
Fas L-negative (n = 13) 1 7 STH + SO (7) 0 PAC (5)
MMC (1)
None (1)
2 2 STH + SO (2) 0 PAC (2)
3 3 STH + SO (3) 1 PAC (2)
CP (1)
4 1 PL (1) 0 PAC (1)
STH: simple total hysterectomy, SO: salpingo-oophorectomy, SRH: semiradical hysterectomy, RH: radical hysterectomy, SCH: supracervical hysterectomy,
PL: probe laparotomy, PAC: cisplatin, doxorubicin and cyclophosphamide, CP: cisplatin and cyclophosphamide, FAM: 5-Fluorouracil, doxorubicin and
mitomycin C, MMC: mitomycin C.
Table 2 Clinicopathological findings in carcinoma patients
Description All (n = 35) Fas L-positive (n = 22) Fas L-negative (n = 13) Statistics
Age 53.1 ± 11.2 54.4 ± 12.0 50.9 ± 9.6 NS
Follow-up period (months)
Range 5–110 6–78 5–110
Median 32 31.5 32.0
Mean 41.3 39.0 45.3
Histology (No. of patients)
Serous 17 13 4
Mucinous 2 0 2
Endometrioid 8 3 5
Clear cell 8 6 2
Clinical stage (No. of patients)
I1 4 7 7
II 4 2 2
III 13 10 3
IV 4 3 1 NS
NS: not significant.1448 S Munakata et al
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(Dakopatts, Glostrup, Denmark, diluted at 1:100), anti-Fas (UB-2;
MBL, Japan, diluted at 1:25), and anti-Fas L (clone 33;
Transduction Laboratories, KY, USA, diluted at 1:50), together
with polyclonal anti-Bax (Dakopatts, diluted at 1:50) antibody.
2¢,5¢-Diaminobenzidine (DAB) was used as a chromogen. Normal
tonsils were obtained as positive control for bcl-2 and Bax. Tonsils
were fixed in 10% buffered formalin and processed routinely.
Jurkat cells (gift from Dr M Nose, Matsuyama, Japan), used as a
positive control for Fas, were fixed in 10% buffered formalin after
centrifugation and routinely processed for paraffin embedding. As
a Fas L-positive control, Phytohaemagglutinin (PHA) activated
Jurkat cells were used. A total of 1 ´ 107 Jurkat cells were culti-
vated and fixed in 10% buffered formalin after incubation in 2%
PHA (Life Technologies, Tokyo, Japan) at 37°C for 5 h. For nega-
tive control, IgG1 isotype (Dakopatts, diluted at 1:25) was used as
a primary antibody on each section. Some of the specimens were
treated with rabbit polyclonal anti-Fas L (C-20, Santa Cruz
Biotechnology, Santa Cruz, CA, USA, diluted 1:100) raised to
residues 260–279 of human Fas L, to confirm the specificity of
monoclonal anti-Fas L (clone 33). Both antibodies showed the
comparable results (data not shown).
Numbers of positively stained cells with each antibody (P) were
scored as 0 (0%), 1 (< 10%), 2 (10–50%), or 3 (> 50%). Staining
intensity (I) was graded semiquantitatively as 0 (none), 1 (weak),
2 (moderate), or 3 (intense). Then values of P ´ I (PI) with ³ 2
were regarded as positive.
Degree of lymphocytic infiltration in the tumour tissue was
graded as 0 (none), 1 (scarce), 2 (moderate) and 3 (massive). Mean
score of lymphocyte infiltration index (LI) was calculated for each
histologic category.
CD3 (Dakopatts) and CD8 (Dakopatts) immunostaining was
performed by ABC method using Elite Vectastain ABC kit (Vector
Laboratories, Inc., CA, USA). After trypsin digestion (0.1% in
phosphate-buffered saline (PBS), 37°C, 40 min, Sigma, MO,
USA) for CD3 or microwave oven heating (100°C, 15 min) for
CD8, the sections were incubated overnight at 4°C with anti-CD3
and CD8 antibodies diluted at 1:100 and 1:200 respectively.
Number of CD3- or CD8-positive lymphocytes per ten high power
fields was calculated in each case.
Statistics
Statistical analysis was performed with Statcel software (OMS,
Japan). The follow-up period for 35 patients with cancers calcu-
lated from the date of initial surgical treatment ranged from 5 to
110 (median 32) months (Table 2). Differences in positive rate
among each histologic category and type along with PI values
among each histologic category were compared by Fisher’s exact
Table 3 Summary of immunohistochmical studies
Number of positive cases (%)
Bcl-2 Bax Fas Fas L
Adenoma 14/36 (39) 27/36 (75) 28/36 (78) 1/36 (3)
a c
LPM 5/33 (15) a 29/33 (88) 27/33 (82) 12/33 (36) d
b
Carcinoma 12/63 (19) 47/63 (75) 43/63 (68) 42/63 (67)
aP < 0.05, bP < 0.01, cP < 0.001, dP < 0.0001.
Table 4 Results of immunohistochemical study according to histological subtype
Number of positive cases (%)
Classification Type Bcl-2 Bax Fas Fas L
Adenoma Serous 14/25 (56) 20/25 (80) 19/25 (76) 1/25 (4)
a
Mucinous 0/10 (0) 7/10 (70) 8/10 (80) 0/10 (0)
Müllerian 0/1 (0) 0/1 (0) 1/1 (100) 0/1 (0)
LPM Serous 4/14 (29) 14/14 (100) 11/14 (79) 9/14 (64)
b b
Mucinous 0/17 (0) 14/17 (82) 14/17 (82) 3/17 (18)
Müllerian 1/2 (50) 1/2 (50) 2/2 (100) 0/2 (0)
Carcinoma Serous 3/33 (9) 24/33 (73) 23/33 (70) 25/33 (76)
Mucinous 0/5 (0) 2/5 (40) 3/5 (60) 1/5 (20)
a
Endometrioid 3/13 (23) 10/13 (77) 10/13 (77) 7/13 (54)
Clear cell 6/12 (50) 11/12 (92) 7/12 (58) 9/12 (75)
aP < 0.01, bP < 0.05.probability test (Armitage, 1987). Actuarial survival curves of the
patients were constructed by the method of Kaplan–Meier (Kaplan
and Meier, 1958), and the significance of the differences was
estimated by log-rank test. Comparison of age distribution was
made by Student’s t-test, and that of clinical stages by
Mann–Whitney  U-test.
RESULTS
Results of immunohistochemical studies are summarized in Tables
3 and 4. Although five patients received chemotherapy prior to
surgery, this did not considerably affect the stainability of histo-
logic sections.
Bcl-2 and Bax
In the normal ovary, stromal cells, granulosa cells and surface
epithelial cells expressed bcl-2. In the neoplasias, bcl-2 expression
was confined in the cytoplasm of epithelial cells, but weak and
heterogenous (Figure 1 A, B). Positive rate for bcl-2 was signifi-
cantly lower in LPM and carcinoma than in adenoma (P < 0.05)
A B
C D
E F
Figure 1 Immunohistochemical analysis of apoptosis related genes. (A) In serous adenoma, epithelial cells were positive for bcl-2 but weak and
heterogenous. (B) In contrast, tumour cells of serous cystadenocarcinoma were negative for bcl-2. (C) Serous adenoma was negative for Fas L. (D) In serous
cystadenocarcinoma, tumour cells showed granular membranous and cytoplasmic staining of Fas L. (E) Serous adenocarcinoma was positive for Fas. Coarse
granular intracytoplasmic staining was observed. (F) Bax was stained in the cytoplasm of serous adenoma. Bars = 20 mm
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(Table 3). PI value of adenoma (1.53 ± 1.89) was significantly
higher than that in LPM (0.42 ± 0.94) and carcinoma (0.74 ± 1.40)
(Figure 2). Difference in positive rate was significant between
serous adenoma and mucinous adenoma (P < 0.01), serous LPM
and mucinous LPM (P < 0.05), and serous carcinoma and clear
cell carcinoma (P < 0.01) (Table 4).
In the normal tonsil, Bax protein was mainly expressed in
germinal centre cells and in basal, parabasal to intermediate cell
layer of squamous epithelium (data not shown). Bax protein was
weakly expressed in the surface cells of normal ovary (data not
shown). There was no significant difference in positive rate for
Bax between adenoma, LPM and carcinoma (Table 3 and
Figure 1F).
Fas and Fas ligand
Fas was expressed on the surface of Jurkat cells and surface cells
of normal ovary (data not shown). In adenoma, LPM, or carci-
noma, not only cell surface but also intra-cytoplasmic staining for
Fas was observed. Some tumour cells showed coarse granular
intracytoplasmic staining (Figure 1E). There was no prominent
difference in the frequency of Fas expression and PI value among
each histologic category of ovarian neoplasias. Fas expression was
not prominent in infiltrating lymphocytes.
Jurkat cells stimulated with PHA expressed Fas L as clusters
near the cell surface. In ovarian neoplasias, Fas L expression was
detected not only on the cell surface but also as granular cyto-
plasmic staining (Figure 1 C, D). Fas L was expressed in only one
of 36 cases (3%) with adenoma but 36% and 67% of cases with
LPM and carcinoma respectively. The difference in positive rate
between each group was significant (Table 3). Difference of PI
values between adenoma (0.22 ± 0.48), LPM (1.63 ± 1.88) and
carcinoma (2.92 ± 1.14) was also significant (Figure 3). By histo-
logical subtype, difference in positive rate was significant between
serous LPM and mucinous LPM (Table 4).
Lymphocyte infiltration and CD3, CD8
Difference in LI values between adenoma (0.86 ± 0.64), LPM
(1.27 ± 0.52) and carcinoma (2 ± 0.70) was significant (Figure 4).
Twenty cases with serous carcinoma (ten with Fas L expression
and ten without) were randomly selected for evaluation of density
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Figure 2 Pl value of bcl-2 in each histologic category. Mean value (± s.d.)
were 1.53 ± 1.89 in adenoma, 0.42 ± 0.94 in LPM and 0.74 ± 1.40 in
carcinoma. Difference was significant between adenoma and LPM (P < 0.01)
or adenoma and carcinoma (P < 0.05)
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Figure 3 Pl value of Fas L in each histologic category. Mean value (± s.d.)
were 0.22 ± 0.48 in adenoma, 1.63 ± 1.88 in LPM and 2.92 ± 1.14 in
carcinoma. Difference was significant between adenoma and LPM
(P < 0.01), LPM and carcinoma (P < 0.01), or adenoma and carcinoma
(P < 0.0001)
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Figure 4 Score of LI in each category. Mean scores of LI in adenoma, LPM
and carcinoma was 0.86 ± 0.64, 1.27 ± 0.52 and 2.00 ± 0.70 respectively.
Difference of scores was significant between adenoma and LPM (P < 0.05),
and LPM and carcinoma (P < 0.0001). Bars indicate standard deviation
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Figure 5 Patients with Fas L-negative carcinomas showed more favourable
prognosis than those with Fas L-positive carcinomas (P = 0.02)Fas L expression in epithelial ovarian neoplasms 1451
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of CD3+ and CD8+ lymphocytes infiltration. In cases with strong
Fas L expression, there was a tendency of less infiltration of CD3-
and CD8-positive lymphocytes, whereas more infiltration of
CD3- and CD8-positive lymphocytes with negative Fas L expres-
sion, although the difference was not significant (data not shown).
Survival analysis
Patients with carcinomas expressing Fas L showed a less
favourable 5-year survival rate (44%) than those without Fas L
expression (92%) (P = 0.02) (Figure 5). Patients with positive
bcl-2 expression showed more favourable prognosis than those
without, although the difference was not significant. Any signifi-
cant correlations between Bax or Fas expressions and survival
were not found (data not shown).
DISCUSSION
In non-small-cell lung carcinoma, breast cancer and ovarian
cancer, patients with negative or weak bcl-2 expression showed
less favourable prognosis than those with distinct bcl-2 expression
(Pezzella et al, 1993; Joensuu et al, 1994; Henriksen et al, 1995).
In the present study, carcinoma patients with negative bcl-2
expression also showed poorer prognosis than those with bcl-2
expression, although the difference was not statistically signifi-
cant. In the study of Henriksen et al (1995), eight of 12 (67%)
cases with benign ovarian tumours were positive for bcl-2 expres-
sion, while 24 of 50 (48%) with carcinomas were bcl-2-positive.
Similar tendency was observed in our study: 14 of 36 (39%)
adenoma cases were bcl-2-positive, whereas five of 33 (15%)
LPM and 12 of 63 (19%) carcinoma cases were bcl-2-positive.
There was a difference in the frequency of bcl-2 expression among
each histologic type: none of mucinous tumours were positive for
bcl-2, whereas, in serous tumours, 14 of 25 (56%) adenoma, four
of 14 (29%) LPM and three of 33 (9%) carcinoma were bcl-2-
positive. Although about a half of cases with clear cell carcinoma
were bcl-2-positive, bcl-2-positive rate generally decreased along
with increase in malignant potential.
Bax is one of the bcl-2 family proteins with 21% homology with
bcl-2 protein. Bax heterodimerizes with bcl-2 protein, and the ratio
of these two peptides control programmed cell death (Oltvai et al,
1993). There have been few reports suggesting a clinical signifi-
cance of Bax expression in cancers. Bax expression correlated
with favourable prognosis of patients in neuroendocrine lung
tumours (Brambilla et al, 1996) or in neuroblastoma (Hoehner
et al, 1997). Wehrli et al (1998) reported that there were no signi-
ficant differences in Bax staining between benign, borderline and
malignant ovarian tumours. Our study also did not reveal any
correlation between Bax expression and histologic classifications
or survival.
Fas is a type I membrane protein that belongs to the TNF
receptor family. Human Fas antigen consists of 325 amino acids
and transduces death signal conferred by anti-Fas antibody or Fas
L. Fas expression was reported in various kinds of human malig-
nancies, including ovarian serous cystadenocarcinoma (Owen-
Schaub et al, 1994; Hellquist et al, 1997; Wakahara et al, 1997). In
our study, 74% of patients with ovarian neoplasms showed Fas
expression without significant difference in the frequency of Fas
expression between histologic types.
Fas L is a type II membrane protein consisting of 281 amino
acids, that belongs to TNF family protein. Fas L induces cell death
via Fas-mediated pathway (Takahashi et al, 1994). It is hypothe-
sized that cancer cells expressing Fas L have an advantage to
evade human immune surveillance. In our study, the frequency of
cases expressing Fas L increased along with increasing malignant
potential. Although statistically not significant, density of CD3+,
CD8+ lymphocytes was higher in the serous carcinoma with nega-
tive Fas L expression than those with strong Fas L expression. The
poorer prognosis of the carcinoma patients expressing Fas L
compared to those without was observed in our series. These find-
ings suggest that Fas L-expressing carcinomas induce apoptosis in
infiltrating lymphocytes with Fas expression, and escape from
immune surveillance. Relatively lower frequency of Fas L expres-
sion in the mucinous tumour suggest the presence of different
mechanism in growth advantage of this tumour. Follow-up period
in our study was relatively short, therefore a further investigation
is required to characterize prognostic value of Fas L expression in
various ovarian epithelial neoplasms.
A large number of ovarian tumours expressed Fas. Why does
apoptosis not occur in Fas-expressing ovarian tumours via co-
expressed Fas L? In some reports, Fas L expressed by tumour cells
was demonstrated to be functional (Hahne et al, 1996; Shiraki
et al, 1997; Ungefroren et al, 1998). So, the dysfunction of Fas-
mediated apoptotic system in the tumour cells will explain this
phenomenon. This might be supported by the study of Shima et al
(1995) showing that two of five myeloma cell lines expressing Fas
on their cell surface was insensitive to agonizing anti-Fas mono-
clonal antibody. There is another possibility that mutated Fas gene
contributes to desensitization of Fas system as reported by
Landowski et al (1997) or localization of Fas antigen in the cyto-
plasm not on the cell surface, as reported in oesophageal carci-
noma by Hughes et al (1997). In our study, many tumours showed
intracytoplasmic staining for Fas antigen along with Fas L. Further
investigation will be required to elucidate the question.
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